Full List of Publications and Presentations by Lawrence B. Afrin, M.D.

Peer-Reviewed Publications

1. Molderings GJ, Haenisch B, Brettner S, Homann J, Dumoulin FL, Panse J, Butterfield J, Afrin LB. Pharmacological treatment options of systemic mast cell activation disease. Naunyn Schmiedebergs Arch Pharmacol 2016 Apr 12. doi: 10.1007/s00210-016-1247-1. PMID: 27132234
2. Afrin LB (2016). A New Era for an Old Cell: Heightened Appreciation of Mast Cell Disease Emerges. Transl Res 2016 Mar 10. pii: S1931-5244(16)00072-4. doi: 10.1016/j.trsl.2016.03.003 [Epub ahead of print]. PMID: 27016701.
3. Afrin LB, Butterfield J, Raithel M, Molderings GJ (2016). Often seen, rarely recognized: mast cell activation disease – a guide to diagnostic and therapeutic options. Ann Med 2016 Mar 25:1-12 [Epub ahead of print], doi: 10.3109/07853890.2016.1161231, PMID: 27012973.
4. Afrin LB (2016). Mast cell activation disease and the modern epidemic of chronic inflammatory disease. Transl Res 2016 Jan 18. pii: S1931-5244(16)00022-0, in press, doi: 10.1016/j.trsl.2016.01.003, PMID: 26850903.
5. Aich A, Afrin LB, Gupta K (2015). Mast cell-mediated mechanisms of nociception. Int J Mol Sci 2015 Dec 4;16(12):29069-92, doi: 10.3390/ijms161226151, PMID: 26690128.
6. Afrin LB, Pöhlau D, Raithel M, Haenisch B, Dumoulin FL, Homann J, Mauer UM, Harzer S, Molderings GJ (2015). Mast Cell Activation Disease: An Underappreciated Cause of Neurologic and Psychiatric Symptoms and Diseases. Brain Behav Immun 2015, doi: 10.1016/j.bbi.2015.07.002, PMID: 26162709.
7. Afrin LB (2015). The Good, The Bad, and The Ugly of the New Doctor-Patient-Computer Relationship of the 21st Century. Journal of the South Carolina Medical Association, 2015 June, doi: pending, PMID: pending.
8. Afrin LB, Cichocki F, Patel K, Molderings GJ (2015). Successful treatment of mast cell activation syndrome with sunitinib. Eur J Haematol 2015 Dec;95(6):595-7, doi: 10.1111/ejh.12606, PMID: 26072665, in press.
9. Afrin LB, Khoruts A (2015). Mast cell activation disease and microbiotic interactions. Clin Ther 2015 May, doi: 10.1016/j.clinthera.2015.02.008, PMID: 25773459, in press.
10. Randall N, Courville EL, Baughn L, Afrin L, Ustun C (2015). Bosutinib, A Lyn/Btk-Inhibiting Tyrosine Kinase Inhibitor, Is Ineffective In Advanced Systemic Mastocytosis. American Journal of Hematology 2015, doi: 10.1002/ajh.23942, PMID: 25641616, in press.
11. Afrin LB, Oates JC, Kamen DL (2014). Improving clinical trial accrual by streamlining the referral process. International Journal of Medical Informatics 2015 Jan;84(1):15-23, doi: 10.1016/j.ijmedinf.2014.09.001, PMID: 25256066.
12. Afrin LB (2014). Mast Cell Activation Syndrome as a Significant Comorbidity in Sickle Cell Disease. American Journal of Medical Sciences 2014 Dec;348(6):460-464, doi: 10.1097/MAJ.0000000000000325, PMID: 25171546.
13. Afrin LB (2014). The presentation, diagnosis, and treatment of mast cell activation syndrome. Curr Allergy Clin Immunol 2014 Sep;27(3):72-83, doi: pending, PMID: pending.
14. Fanning S, Stephenson J, Afrin LB, Kistner-Griffin E, Bentz T, Stuart RK (2014). Sequential Ofatumumab and Lenalidomide for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma. Leuk Lymphoma 2014 Aug 17:1-15, doi: 10.3109/10428194.2014.935369, PMID: 25130476, in press.
15. Afrin LB, Spruill L, Schabel S, Pierce-Young J (2014). Improved metastatic uterine papillary serous cancer outcome with treatment of mast cell activation syndrome. Oncology 28(2):129-131,134, PMID: 24701700.
16. Afrin LB, Molderings GJ (2014). A concise, practical guide to diagnostic assessment for mast cell activation disease. World J Hematol 3(1):1-17, doi:10.5315/wjh.v3.i1.1.
17. Afrin LB. Utility of hydroxyurea in mast cell activation syndrome (2013). Experimental Hematology and Oncology 2:28, pp. 1-8, http://www.ehoonline.org/content/2/1/28, doi:
10.1186/2162-3619-2-28, PMID: 24192267.
18. Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O’Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S (2013). Interim Analysis of Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts. Journal of Hematology and Oncology 29;6(1):81, pp. 1-10, doi:10.1186/1756-8722-6-81, PMID: 24283202.
19. Afrin LB (2013). Non-histaminergic idiopathic angioedema may be a presentation of mast cell activation syndrome. J Investig Allergol Clin Immunol 23(3):212, PMID: 23967766.
20. Afrin LB (2012). Sclerosing Mediastinitis and Mast Cell Activation Disorder. Pathology Research and Practice 208(3):181-185, doi:10.1016/j.prp.2011.12.005, PMID: 22296862.
21. Afrin LB (2012). Mast Cell Activation Disorder Masquerading as Agranulocytosis. Military Medicine 177(1):113-117, PMID: 22338992.
22. Saddoughi SA, Garrett-Mayer E, Chaudhary U, O’Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS, Bostick R, Senkal CE, Hannun YA, Bielawski J, Simon G, Shirai K, Ogretmen B (2011). Results of a Phase II Trial of Gemcitabine Plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-Ceramide as a Novel Biomarker for Monitoring Response. Clinical Cancer Research 17(18):6097-6105, doi: 10.1158/1078-0432.CCR-11-0930, PMID: 21791630.
23. Molderings GJ, Brettner S, Homann J, Afrin LB (2011). Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. Journal of Hematology and Oncology 4:10, pp. 1-8, http://www.jhoonline.org/content/4/1/10, doi: 10.1186/1756-8722-4-10; PMID: 21418662.
24. Afrin LB (2011). Polycythemia from Mast Cell Activation Syndrome: Lessons Learned. American Journal of Medical Sciences 342(1):44-49, doi: 10.1097/MAJ.0b013e31821d41dd, PMID: 21642812.
25. Afrin LB (2011). Burning Mouth Syndrome and Mast Cell Activation Disorder. Oral Med Oral Surg Oral Path Endodont 111(4):465-72, doi: 10.1016/j.tripleo.2010.11.030, PMID: 21420635.
26. Afrin LB, Afrin JB (2011). Value of Preemptive CYP2C19 Genotyping in Allogeneic Stem Cell Transplant Patients Considered for Pentamidine Administration. Clinical Transplantation 25(3):E271-E275, doi: 10.1111/j.1399-0012.2011.01399.x, PMID: 21299635.
27. Afrin LB (2010). Mast Cell Activation Disorder Masquerading as Pure Red Cell Aplasia. International Journal of Hematology 91(5):907-908, doi: 10.1007/s12185-010-0605-x, PMID: 20526893.
28. Afrin LB (2010). Fatal Copper Deficiency from Excessive Use of a Popular Zinc-Based Denture Adhesive. American Journal of Medical Sciences 340(2):164-168; doi: 10.1097/MAJ.0b013e3181e3648c; PMID: 20555248.
29. Serber ER, Finch NJ, Afrin LB, Greenland WJ (2010). Using a Webcasting Support Service: Experiences of In-Person Attendees of an Implantable Cardioverter Defibrillator Support Group. Heart and Lung 39(2):94-104, doi: 10.1016/j.hrtlng.2009.06.003; PMID: 20207269.
30. Demiris G, Afrin LB, Courtney KL, Goossen W, Lovis C, Lynch C, Sondhi M, Speedie S, Vimarlund V (2008). Patient-centered applications: use of information technology to promote disease management and wellness – a white paper by the AMIA Knowledge in Motion Working Group. Journal of the American Medical Informatics Association 15(1):8-13, PMID: 17947617.
31. Afrin LB, Arana GW, Medio F, Ybarra A, Clarke H (2006). Improving Oversight of the Graduate Medical Education Enterprise: One Institution’s Strategies and Tools. Academic Medicine 81(5):419-425, PMID: 16639192.
32. Afrin LB (2005). General medicine in South Carolina, 1905-2005: the science and the art as recorded in The Journal of the South Carolina Medical Association. Journal of the South Carolina Medical Association 101(5):129-136, PMID: 16187488.
33. Onitilo A (fellow), Lin Y, Okonofua E, Afrin L, Tilley B (2004). Race, Education and Knowledge of Bone Marrow Registry: Indicators of Willingness to Donate Bone Marrow Among African Americans and Caucasians. Transplantation Proceedings 36(10):3212-3219, PMID: 15686731.
34. Kokko H, Hall PD, Afrin LB (2002). Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion. Pharmacotherapy 22(9):1188-92, PMID: 12222557.
35. Ergul S (fellow), Lal A, Afrin L, Frei-Lahr D (2002). Primary Mediastinal Large B-Cell Lymphoma. Southern Medical Journal 95(9):1005-1007, PMID: 12356098.
36. Afrin LB, Ergul SM (2000). Medical Therapy of Prostate Cancer: 1999. Journal of the South Carolina Medical Association 96(2):77-84, PMID: 10710906.
37. Afrin LB (1999). Web Access to the American Society of Hematology Slide Bank. Blood 93(7):2425-2426, PMID: 10215352.
38. Afrin LB (1997). Tumor Boards on the Intranet: Decreasing Administration, Increasing Education. Journal of Registry Management 24(4):128-132.
39. Afrin L, Kuppuswamy V, Slater B, Stuart R (1997). The Physicians Research Network: Improved Access to Information about Clinical Trials. Carolina Health Services and Policy Review 4:127-143.
40. Afrin L, Kuppuswamy V, Slater B, Stuart R (1997). Electronic Clinical Trial Protocol Distribution via the World-Wide Web: Reducing Costs and Errors, Improving Accrual, and Saving Trees. Journal of the American Medical Informatics Association 4(1):25-35, doi: 10.1136/jamia.1997.0040025, PMID: 8988471. Selected for republication in the International Medical Informatics Association’s 1998 Yearbook of Medical Informatics.
41. Tagge E, Chandler J, Harris B, Czako M, Marton L, Willingham M, Burbage C, Afrin L, Frankel A (1996). Preproricin expressed in Nicotiana tabacum cells in vitro is fully processed and bio-logically active. Protein Expression and Purification 8(1):109-118, PMID: 8812841.
42. Afrin LB, Frankel A, Gulick H, Willingham M, Vesely J (1994). Expression of oligohistidine-tagged ricin B chain in Spodoptera frugiperda. Bioconjugate Chemistry 5(6):539-546, PMID: 7533004.
43. Frankel A, Roberts H, Gulick H, Afrin L, Willingham M, Vesely J (1994). Expression of ricin B chain in Spodoptera frugiperda. Biochemical Journal 303(Pt 3):787-794, PMID: 7980448.
44. Afrin LB, Stuart RK (1994). Medical therapy of prostate cancer. Journal of the South Carolina Medical Association 90(5):205-58, PMID: 8028295.
45. Ornstein SM, Markert GP, Johnson AH, Rust PF, Afrin LB (1988). The effect of physician personality on laboratory test ordering for hypertensive patients. Medical Care 26(6):536-43, PMID: 3379985.
46. Ornstein S, Johnson A, Markert G, Afrin L (1987). Association between family medicine residents’ personality and laboratory test-ordering for hypertensive patients. Journal of Medical Education 62(7):603-605, PMID: 3110420.

Non-Peer-Reviewed Publications

1. Afrin LB (2016). Symptoms of Mast Cell Activation Disease. Invited contribution to http://www.tmsforacure.org, the website of The Mastocytosis Society.
2. Afrin LB (2011). What I have learned since fellowship: tips for professional success and happiness. Oncology Fellows 3(1):2-6.
3. Afrin LB (2007). Public Policy and Ethical Issues in Mobile Computing for Disease and Wellness Management. An invited podcast prepared for the series, “IT and Patient Empowerment,” developed by the Knowledge-in-Motion Working Group of the American Medical Informatics Association, introduced at http://www.amia.org/mbrcenter/wg/kim/documents.asp and accessed directly at http://www.amia.org/podcasts/mp3/kim/kim_3_medinfo2007.mp3, initially placed on-line on October 25, 2007.
4. Afrin LB, Evans RM, Mitchell K, DeTeresa RM, Ko D, Stahl DC (2007). Improving the Automated Discovery of Clinical Trials via Web Services: Progress on a Standards Initiative of the Association of American Cancer Institutes. http://www.aaci-cancer.org/pdf/2005_informatics.pdf. Dr. Afrin created the concept, led the multi-institutional development team, developed local software, and drafted the manuscript.
5. Afrin LB (1996). Medical Informatics: A New Specialty for the ’90s and Beyond. Medical Alumni Today, Summer 1996.

Electronic Publications

1. Afrin LB (2015). Utility of Continuous Diphenhydramine Infusion in Severe Mast Cell Activation Syndrome. Blood 126:5194, http://www.bloodjournal.org/content/126/23/5194.
2. Zenker N, Afrin LB (2015). Utilities of Various Mast Cell Mediators in Diagnosing Mast Cell Activation Syndrome. Blood 2015 126:5174, http://www.bloodjournal.org/content/126/23/5174.
3. Afrin LB, Wan Z, Hill E (2013). Characterization of Common Blood Test Abnormalities Potentially Aiding Diagnosis of Mast Cell Activation Syndrome: A Preliminary Analysis. Blood 122(21):5420, http://bloodjournal.hematologylibrary.org/content/122/21/5240.abstract.
4. Afrin LB, Afrin JB (2012). Preemptive CYP2C19 Genotyping in Acquired Aplastic Anemia Treated with Immunosuppressive Therapy May Help Avoid Confounding Non-Response Due to Pentamidine Myelotoxicity. (e-Letter.) Blood, 2012 Aug 17, http://bloodjournal.hematologylibrary.org/content/early/2012/06/06/blood-2012-04-421883/reply#bloodjournal_el_7176, published on-line response to Scheinberg P, Young NS. How I Treat Acquired Aplastic Anemia. Blood 2012;120:1185-1196.
5. Afrin LB (2011). KIT-D816V in Acute Myelogenous Leukemia May Signify Co-Presence of Mast Cell Disease. (e-Letter.) Blood, 2011 Mar 24, http://bloodjournal.hematologylibrary.org/content/117/10/2775.full/reply#bloodjournal_el_1405, published on-line response to Park JH, Hedvat CV, Tallman MS. Blood consult: acute myeloid leukemia and the t(8;21)(q22;22). Blood 2011 Mar 10;117(10):2775-2777.
6. Afrin LB, Afrin JB (2011). Value of Preemptive CYP2C19 Genotyping in Allogeneic Stem Cell Transplant Patients Considered for Pentamidine Administration. Clinical Transplantation 25(3):E271-E275, http://onlinelibrary.wiley.com/doi/10.1111/j.1399-0012.2011.01399.x/pdf, doi: 10.1111/j.1399-0012.2011.01399.x, PMID: 21299635.
7. Afrin LB (2007). Public Policy and Ethical Issues in Mobile Computing for Disease and Wellness Management. An invited podcast prepared for the series, “IT and Patient Empowerment,” developed by the Knowledge-in-Motion Working Group of the American Medical Informatics Association, introduced at http://www.amia.org/mbrcenter/wg/kim/documents.asp and accessed directly at http://www.amia.org/podcasts/mp3/kim/kim_3_medinfo2007.mp3, initially placed on-line on October 25, 2007.
8. Afrin LB, Evans RM, Mitchell K, DeTeresa RM, Ko D, Stahl DC (2007). Improving the Automated Discovery of Clinical Trials via Web Services: Progress on a Standards Initiative of the Association of American Cancer Institutes. http://www.aaci-cancer.org/pdf/2005_informatics.pdf.

Books

1. Afrin LB. Never Bet Against Occam: Mast Cell Activation Disease and the Modern Epidemics of Chronic Illness and Medical Complexity. Sisters Media, LLC, 2016, 480 pages, ISBN-13: 978-0997319613. (Mass market hardback/softback/e-book, explaining mast cell disease to the lay community. Conceived and singlehandedly written by Dr. Afrin 2013-2015.)
2. Simone JV, Afrin LB, Byers T, et al. (Institute of Medicine Committee on Assessing Improvements in Cancer Care in Georgia) (2005). Assessing the Quality of Cancer Care: An Approach to Measurement in Georgia; Eden J, Simone JV, eds., The National Academies Press. (IOM committee member, participated in meetings, helped assess data and make recommendations.)

Chapters in Books

1. Afrin L.B. (2015). Mast cell activation syndrome: a chameleon that confounds diagnostics and treatment for other disorders. The Dysautonomia Project: Understanding Autonomic Nervous System Disorders for Physicians and Patients; Freeman K, Goldstein DS, Thompson CR, eds., Bardolf & Company, Sarasota, FL, ISBN 978-1-938842-24-5, pp. 135-139.
2. Afrin L.B. (2013). Presentation, Diagnosis, and Management of Mast Cell Activation Syndrome. Mast Cells: Phenotypic Features, Biological Functions, and Role in Immunity; Murray, D., ed., Nova Science Publishers, ISBN 1626181667, 9781626181663, pp. 155-231, available on-line at https://www.novapublishers.com/catalog/product_info.php?products_id=42603.
3. Afrin L.B., Clark F., Waller J., Cawley P., Hartzog T., Daniels M., Campbell D (2010). If It Ain’t Broke, Don’t Fix It: Replacing an HIS. H.I.T. or Miss: Lessons Learned from Health Information Technology Implementations; Leviss J., ed., American Health Information Management Association, ISBN 1584263970, 9781584263975, pp. 47-51. Dr. Afrin was co-director of the project described and for the chapter served as guarantor of integrity, developed the concept, and wrote the manuscript.
4. Afrin L.B., del Bene V.M. (1995). Physician Workstations. Health Care Information Management Systems: A Practical Guide, 2nd Edition; Ball M, Douglas J, Albright J, Simborg D, eds., Springer-Verlag, ISBN 978-1-4757-2404-2, doi: 10.1007/978-1-4757-2402-8, pp. 17-42. Invited review. Dr. Afrin wrote the manuscript.

Presentations

Invited Oral Presentations at International Professional Meetings, Conferences, etc.

1. “The Bulk of the Iceberg Revealed: Mast Cell Activation Syndrome.” Presentation to patients, Wellcome Collection, London, UK, October 17, 2015.
2. “The Bulk of the Iceberg Revealed: Mast Cell Activation Syndrome.” Presentation to physicians, Wellcome Collection, London, UK, October 17, 2015.
3. “Mast Cell Activation Disease: The Most Underconsidered Cause of Idiopathic Neurologic and Psychiatric Illness.” Invited grand rounds at Department of Neurogenerative Diseases, University Hospitals Bonn, Bonn, Germany, October 14, 2015.
4. “The Prevalence of Mast Cell Activation Disease: A Quintessential Challenge for the New Century.” Invited grand rounds at Middlemore Hospital, Counties Manukau Health, Auckland, New Zealand, September 10, 2015.
5. “The Prevalence of Mast Cell Activation Disease: A Quintessential Challenge for the New Century.” Invited grand rounds at Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand, September 9, 2015.
6. “The Prevalence of Mast Cell Activation Disease: A Quintessential Challenge for the New Century.” Invited grand rounds at Tauranga Hospital, Bay of Plenty District Health Board, Tauranga Hospital, Tauranga, New Zealand, September 8, 2015.
7. “The Prevalence of Mast Cell Activation Disease: A Quintessential Challenge for the New Century.” Invited presentation at Waikato District Health Board, Waikato Hospital, Waikato, New Zealand, September 4, 2015.
8. “The Prevalence of Mast Cell Activation Disease: A Quintessential Challenge for the New Century.” Invited presentation at Southern District Health Board, Invercargill Hospital, Invercargill, New Zealand, September 1, 2015.
9. “The Prevalence of Mast Cell Activation Disease: A Quintessential Challenge for the New Century.” Department of Haematology, Dunedin Hospital, Dunedin, New Zealand, August 31, 2015.
10. “Mast Cell Activation Disease: Case Discussions.” Oamaru Medical Center, Oamuru, New Zealand, August 30, 2015.
11. “The Prevalence of Mast Cell Activation Disease: A Quintessential Challenge for the New Century.” Invited grand rounds at Christchurch Hospital, Christchurch, New Zealand, August 28, 2015.
12. “The Prevalence of Mast Cell Activation Disease: A Quintessential Challenge for the New Century.” Invited presentation at Capital and Coast District Health Board, Division of Hematology/Oncology, Wellington, New Zealand, August 26, 2015.
13. “The Prevalence of Mast Cell Activation Disease: A Quintessential Challenge for the New Century.” Invited presentation at University of Otago – Wellington, Pathology Seminar, Wellington, New Zealand, August 25, 2015.
14. “Systemic Mast Cell Disease: Challenging Cases.” Invited discussant, 2014 Annual Congress, The Allergy Society of South Africa, Durban, South Africa, August 10, 2014.
15. “Systemic Mast Cell Disease: An Update.” Invited presentation at the 2014 Annual Congress, The Allergy Society of South Africa, Durban, South Africa, August 9, 2014.
16. “Systemic Mast Cell Disease: An Update.” Grand rounds, Division of Allergy and Immunology, University of Cape Town, Cape Town, South Africa, August 6, 2014.
17. “Systemic Mast Cell Disease: An Update.” Invited presentation at the University of Toronto Women’s College Hospital, sponsored by The Mastocytosis Society of Canada, Toronto, Ontario, Canada, June 6, 2011.
18. “Linking Data to Knowledge at the Point of Care.” 2011 Oacis Users Group Meeting, Toronto, Ontario, Canada, June 6, 2011.
19. “Noah, Redux: Preparing Clinicians for the Twin Information Tsunamis of the 21st Century.” Keynote presentation, 2011 Canadian Conference on Medical Education, Toronto, Ontario, Canada, May 9, 2011.
20. “Mast Cell Activation Disorder.” 5th International Workshop on Chronic Myelogenous Leukemia and Myeloproliferative Neoplasms, Orland, FL, December 8, 2010.
21. “The Path to Progress Is Not Always a Straight Line: A Review of MUSC’s EMR Work (ca. 1970 – Present).” Oacis User Group 2008 Annual Meeting, Montreal, Quebec, June 4, 2008.
22. “Public Policy and Ethical Issues in Patient-Centered Applications and Mobile Health: Use of Information Technology to Promote Disease Management and Wellness.” MedInfo 2007 (triennial meeting of the International Medical Informatics Association), Brisbane, Australia, August 19, 2007.
23. “Carts and Horses: Questing for Interoperability Among U.S. Electronic Medical Record Systems While Still Struggling for Operability.” Oacis User Group 2007 Annual Meeting, Adelaide, Australia, August 14, 2007.
24. “Improved Patient Support through Support Group Webcasting: A Feasibility Assessment.” Thirty-Eighth Annual Hawaii International Conference on Systems Sciences, Waikoloa, Hawaii, January 5, 2005.
25. “How to Implement an Electronic Residency Management System: from Soup to Nuts.” 2004 Annual Meeting of the Association of American Medical Colleges’ Group on Resident Affairs, Vancouver, BC, April 18, 2004.

Invited Oral Presentations at National Professional Meetings, Conferences, etc.

1. “The Bulk of the Iceberg Revealed: Mast Cell Activation Syndrome.” Invited grand rounds, Department of Pediatrics, Florida Hospital for Children, Orlando, Florida, December 3, 2015.
2. “Mast Cell Activation Syndrome: 2014 Update.” The Mastocytosis Society, 2014 Annual Meeting, Rochester, MN, September 19, 2014.
3. “Automated Assistance to Less Compliant Duty-Hour Loggers – 2013 Update.” Annual E*Value Users Conference, Minneapolis, MN, October 11, 2013.
4. “Mast Cell Activation Syndrome.” Grand Rounds, Division of Hematology/Oncology, Vanderbilt University, Nashville, TN, October 30, 2013.
5. “Mast Cell Activation Syndrome.” Grand Rounds, Division of Hematology/Oncology, University of Miami, Miami, FL, October 2, 2013.
6. “Mast Cell Activation Syndrome: Characterization of 298 Patients.” The Mastocytosis Society, 2013 Annual Meeting, Greenville, SC, September 27, 2013.
7. “Mast Cell Activation Syndrome: Approach to Diagnosis.” The Mastocytosis Society, 2013 Annual Meeting, Greenville, SC, September 27, 2013.
8. “Update in Chronic Myeloproliferative Neoplasms.” Invited presentation to the South Carolina Oncology Society, 2013 Annual Meeting, Charleston, SC, August 2013.
9. “Mast Cell Activation Syndrome.” The Mastocytosis Society, 2012 Annual Meeting, Seattle, WA, October 12, 2012.
10. “Mast Cell Activation Syndrome.” Invited panel discussant, 2011 Annual Meeting of The Mastocytosis Society, Boston, MA, October 27, 2011.
11. “An Enhanced Resident Duty Hour Logging Warning System.” 2011 E*Value Users Group Meeting, Minneapolis, MN, October 14, 2011.
12. “Improved GME Enterprise Management Using E*Value Dashboard Reports.” E*Value Annual User Conference, Minneapolis, MN, October 7, 2010.
13. “Interfacing Third-Party Conference Attendance Tracking Systems to E*Value.” E*Value Annual User Conference, Minneapolis, MN, October 7, 2010.
14. “Not a Common Drug Overdose: Severe GI Toxicity from Aripiprazole due to a Cytochrome p450 2D6 Polymorphism.” (presented by Aravapalli A), Southern Hospital Medicine Conference, New Orleans, LA, October 16, 2009.
15. “The Bane of the Modern Clinician: Bridging the Data-Knowledge Divide.” Invited keynote address, Oacis User Group 2009 Annual Meeting, Charleston, SC, April 27, 2009.
16. “Using a Support Group Webcasting Service: Experiences of Patients and Caregivers with Implantable Defibrillators.” (Finch N (presenting), Afrin LB.) Proceedings of the Florida International University School of Nursing’s Annual Research Conference: Improving Health Care Quality Through Research, Miami, FL, October 21, 2005.
17. “Improved Inter-Institutional Research Collaboration via a Virtual Hallway.” 2005 Annual Symposium of the American Telemedicine Association, Denver, CO, April 19, 2005.
18. “Improved Patient Support through Support Group Webcasting: A Feasibility Assessment.” 2005 Annual Symposium of the American Telemedicine Association, Denver, CO, April 20, 2005.
19. “Electronic Residency Management System Implementation from Soup to Nuts.” 2004 Annual Meeting of the Alliance for Academic Internal Medicine, October 16, 2004, Nashville, TN.
20. “Rapid Development of Mobile Applications: Theory and Practice,” American Medical Informatics Association 2004 Annual Symposium (tutorial), San Francisco, CA, September 7, 2004.
21. “Open EMR Architecture Advantages for Clinical Trial Accrual.” Oacis User Group 2004 Annual Meeting, San Francisco, CA, May 25, 2004.
22. “Electronic Residency Management System Implementation from Soup to Nuts.” 2004 Annual Meeting of the Association of American Medical Colleges’ Group on Information Resources, Salt Lake City, UT, May 3, 2004.
23. “Open Electronic Medical Record Architecture Running on the Sun Platform: A Case Study.” Health Information Management Systems Society 2004 Annual Symposium, Orlando, FL, February 25, 2004.
24. “Web Services-Based Access to Local Clinical Trial Databases: A Standards Initiative of the Association of American Cancer Institutes.” (Stahl DC (presenting), Evans Jr. RM, Afrin LB, DeTeresa RM, Ko D, Mitchell K.) Annual Symposium of the American Medical Informatics Association, Proc Amer Med Info Assoc, Washington, D.C., November 10, 2003.
25. “Open EMR Architecture Advantages for Clinical Trial Accrual.” American Medical Informatics Association 2003 Annual Symposium, Washington, DC, November 10, 2003.
26. “Rapid Development of Mobile Applications: Theory and Practice,” American Medical Informatics Association 2003 Annual Symposium (tutorial), Washington, DC, November 9, 2003.
27. “Open EMR Architecture Advantages for Clinical Trial Accrual.” Toward an Electronic Patient Record (TEPR) 2003 Annual Meeting, San Antonio, TX, May 13, 2003.
28. “Open Architecture Advantages for EMR-PACS Integration.” Toward an Electronic Patient Record (TEPR) 2003 Annual Meeting, San Antonio, TX, May 12, 2003.
29. “Building Dynamic, Enterprise Resource-Integrated Web Applications: Theory and Practice with ColdFusion,” American Medical Informatics Association 2002 Annual Symposium (tutorial), San Antonio, TX, November 9, 2002.
30. “Rapid Development of Mobile Applications: Theory and Practice,” American Medical Informatics Association 2002 Annual Symposium (tutorial), San Antonio, TX, November 10, 2002.
31. “Automation-Based Methods of Finding Patients for Clinical Trials,” American Medical Informatics Association 2002 Spring Symposium, Invited Expert/Facilitator on Clinical Trials Informatics, Scottsdale, AZ, May 20-22, 2002.
32. “Using eTechnologies to Add Value for the Clinical Trial Investigator,” Second Annual Conference on Web-Based Clinical Trials: Apply Wireless and Internet Technologies to Improve Trial Efficiency, Philadelphia, PA, September 10-12, 2001.
33. “Rapid Development of Mobile Applications: Theory and Practice,” American Medical Informatics Association 2001 Annual Symposium (tutorial), Washington, DC, November 4, 2001.
34. “Oacis at MUSC: Our Emerald Centerstone,” Keynote presentation, Oacis Healthcare User Group 1999 Annual Meeting, Kiawah Island, SC, April 13, 1999.
35. “Open Architecture EMR Technologies.” PACS: A “How To” Conference. Charleston, SC, March 16, 1999.
36. “Information Technology and Doctors.” Maryland Society of Healthcare Information Systems Management, Baltimore, MD, March 11, 1999.
37. “Using Cold Fusion as an Application Development Tool in Healthcare.” Internet Working Group, American Medical Informatics Association 1998 Annual Symposium, Orlando, FL, November 10, 1998.
38. “Protein A Column.” Workshop on Autoimmune (Idiopathic) Thrombocytopenic Purpura: Pathogenesis and New Approaches to Therapy, sponsored by the National Heart, Lung, and Blood Institute of the National Institutes of Health, Bethesda, Maryland, August 18-19, 1997.
39. “Healthcare Information Security and Confidentiality.” Panelist, Offsite Conference of the Healthcare Information Infrastructure Technology program, Jekyll Island, GA, March 21, 1996.
40. “Physicians Research Network (PRN) Security.” Presentation at Offsite Conference of the Healthcare Information Infrastructure Technology program, Jekyll Island, GA, March 21, 1996.
41. “Research Uses of Clinical Data Repositories: Panning for Gold in Them Thar Terabytes.” Oacis Healthcare Systems, Inc.-sponsored Conference on Academic Uses of Clinical Data Repositories, Greenbrae, CA, March 9, 1996.
42. “The Physicians Research Network: A World-Wide Web Interface to the OACIS Clinical Data Repository.” OACIS Quality Council Spring 1996 meeting, Pasadena, CA, May 4, 1996.

Invited Oral Presentations at Local and Regional Professional Meetings, Conferences, etc.

1. “Mast Cell Disease: Current Concepts and Progress.” Department of Medicine Research Conference Series, University of Minnesota, Minneapolis, MN, April 18, 2016.
2. “Mast Cell Activation Disease: Concepts and Progress.” Garibaldi Lecture Series, Division of Hematology, Oncology & Transplantation, University of Minnesota, Minneapolis, MN, January 22, 2016.
3. “The New Kid on the Mast Cell Disease Block: Mast Cell Activation Syndrome and its Emergency Management.” Emergency Medicine Grand Rounds, Medical University of South Carolina, Charleston, SC, June 6, 2013.
4. “Anemia: Basic Considerations.” Grand Rounds, Department of Obstetrics & Gynecology, Medical University of South Carolina, Charleston, SC, September 18, 2012.
5. “Systemic Mast Cell Disease: An Update.” Nephrology Research Group, Medical University of South Carolina, Charleston, SC, January 18, 2012.
6. “Systemic Mast Cell Disease: An Update.” Division of Hematology/Oncology Grand Rounds, Medical University of South Carolina, April 15, 2011.
7. “Mast Cell Activation Disorder.” Division of Rheumatology Grand Rounds, Medical University of South Carolina, Charleston, SC, August 6, 2010.
8. “Hot Topics in Medical Informatics: 2005.” Internal Medicine Grand Rounds, Medical University of South Carolina, Charleston, SC, May 17, 2005.
9. “Electronic Systems for Tumor Board Management and Tumor Registry Data Mining at MUSC,” South Carolina Cancer Registrars Association Spring 2003 Educational Conference, Charleston, SC, April 3, 2003.
10. “Use of PDAs in Learning and Teaching,” MUSC Apple Tree Society, Charleston, SC, March 5, 2003.
11. “Medical Informatics Update 2001: Pleasure, Pain, and Promises,” Medical University of South Carolina Department of Internal Medicine Grand Rounds, Charleston, SC, September 18, 2001.
12. “Management of Hormone-Refractory Prostate Cancer: 2001,” University of South Carolina Department of Internal Medicine Grand Rounds, Richland Memorial Hospital, Columbia, SC, January 4, 2001.
13. “Computer and Internet Skills for Physicians.” Twenty-First Annual Carolina Cup Symposium: Update ‘99 in Clinical Pediatrics and Family Medicine, Columbia, SC, March 26, 1999.
14. “Management of Androgen-Independent Prostate Cancer,” speaker and panelist, Prostate Cancer Forum, Carolina Urological Association Meeting, Charleston, SC, August 21, 1999.
15. “The Search for Signs of Intelligent Data on the Net: Tips for Clinicians on Locating Useful On-Line Biomedical Information.” The South Carolina Cancer Center, Columbia, SC, June 24, 1998.
16. “Web-Based Clinical Trials Information for Patients and the Public.” Hollings Cancer Center Citizens Advisory Council, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, June 19, 1998.
17. “Web-Based Clinical Trials Information for Patients and the Public.” Research Committee, Institute of Psychiatry, Medical University of South Carolina, Charleston, SC, June 16, 1998.
18. “Web-Based Clinical Trials Information for Patients and the Public.” Hollings Cancer Center Board of Directors, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, June 12, 1998.
19. “Tumor Boards on the Intranet: Decreasing Administration, Increasing Education.” South Carolina Cancer Registrars Association, Spring Educational Conference, Shaw Air Force Base, Columbia, SC, March 26, 1998.
20. “The Search for Signs of Intelligent Data on the Net: Tips for Clinicians on Locating Useful On-Line Biomedical Information.” Research Grand Rounds, Medical University of South Carolina, Charleston, SC, October 14, 1997.